Aerovate Therapeutics, Inc.

NasdaqGM:AVTE Stock Report

Market Cap: US$77.7m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Aerovate Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Tim Noyes

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage19.07%
CEO tenure3.9yrs
CEO ownershipn/a
Management average tenure3.5yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Analysis Article • Oct 01

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 11

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension. AV-101 can become standard of care for PAH, when added to background therapy for PAH patients, if it can be shown to be superior to Merck's Winrevair. Read the full article on Seeking Alpha
Analysis Article • May 24

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 09

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 17

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 04

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 28

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Aerovate Therapeutics...
Analysis Article • Jan 06

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Key Insights Aerovate Therapeutics' estimated fair value is US$27.2 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Oct 14

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jul 01

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 22

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 30

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Tim Noyes's remuneration changed compared to Aerovate Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$49m

Dec 31 2024n/an/a

-US$70m

Sep 30 2024n/an/a

-US$85m

Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$70m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$57m

Dec 31 2022US$704kUS$563k

-US$52m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$5mUS$437k

-US$23m

Compensation vs Market: Tim's total compensation ($USD3.07M) is above average for companies of similar size in the US market ($USD660.85K).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.

CEO

Tim Noyes (62 yo)

3.9yrs
Tenure
US$3,070,657
Compensation

Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...

Leadership Team

NamePositionTenureCompensationOwnership
Timothy Noyes
CEO & Director3.9yrsUS$3.07mno data
George Eldridge
CFO & Treasurer4.1yrsUS$2.13m0.017%
$ 13.5k
Benjamin Dake
Founder6.8yrsUS$2.88m0.049%
$ 38.2k
Ralph Niven
Chief Scientific Officer2.7yrsUS$433.20k0.0056%
$ 4.3k
Hunter Gillies
Chief Medical Officer4.9yrsUS$1.63m0.019%
$ 15.0k
Donna Dea
Head of Regulatory Affairs4.6yrsno datano data
Susan Fischer
Executive Vice President of Development Operations3yrsno datano data
Stephen Yu
Senior Vice President of Quality2.7yrsno datano data
Sanjeev Khindri
Executive Vice President of Clinical Development2.3yrsno datano data
Cheryl Lassen
Senior Vice President of Clinical Development2.3yrsno datano data
3.5yrs
Average Tenure
61yo
Average Age

Experienced Management: AVTE's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Timothy Noyes
CEO & Director4yrsUS$3.07mno data
Christian Schade
Independent Director1.8yrsno datano data
Donald Santel
Independent Director2.3yrsUS$568.54k0%
$ 0
David Grayzel
Independent Director4.7yrsUS$225.99k0%
$ 0
Joshua Resnick
Independent Director4.7yrsUS$174.80k0%
$ 0
Mark Iwicki
Independent Director4.2yrsUS$218.30k0%
$ 0
Allison Dorval
Independent Director3.8yrsUS$185.80k0%
$ 0
Habib Dable
Independent Chairman of the Board1.8yrsUS$363.25k0%
$ 0
3.9yrs
Average Tenure
57yo
Average Age

Experienced Board: AVTE's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/29 19:59
End of Day Share Price 2025/04/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aerovate Therapeutics, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vasiliana MoussatosWedbush Securities Inc.
Laura ChicoWedbush Securities Inc.